Synthesis and Antitumor Activity of New Amphiphilic Alkylglycerolipids Substituted with a Polar Head Group, 2-(2-Trimethylammonioethoxy)ethyl or a Congeneric Oligo(ethyleneoxy)ethyl Group

Chemical and Pharmaceutical Bulletin

Volumn 37, Issue 12, 1989, Pages 3277-3285

  Yoshio Honma, Y H ^a   Hozumi, Motoo ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

0 octadnrvl 7 r) f? nvnmiHmvn U r) f? .O trimpthvl3mmrmir ; antitumor activity; cell KB structure activity relationship alkyl; ethoxy) ethyllglycerol; glycerolipid alkyl lysophospholipid 1 <; leukemia cell HL 60 human epidermoid carcinoma; mammary carcinoma MM46 human promyelocytic; nonphosphorus lysoglycerolipid; sarcoma S180

Indexed keywords

2 [2 [2 METHOXY 3 (OCTADECYLOXY)PROPOXY]ETHOXY]ETHYLTRIMETHYLAMMONIUM CHLORIDE; GLYCEROLIPID; THROMBOCYTE ACTIVATING FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN KB; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

AMMONIUM COMPOUNDS; ANIMAL; ANTINEOPLASTIC AGENTS; CHEMISTRY; GLYCERYL ETHERS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED ICR; POLYETHYLENE GLYCOLS; SARCOMA 180; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0024935035     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.37.3277     Document Type: Article

References (26)

1. Present address: Research & Development Division, Eisai Co., Ltd., Tokodai, Tsukuba-shi, lbaraki 300–26, Japan.
2. W. E. Berdel, R. Andreesen and P. G. Munder, “Phospholipids and Cellular Regulation,’ Vol. 2, ed. by J. F. Kuo, CRC Press, Inc., Boca Raton. Florida, 1985. Pp. 41—73.
3. W. E. Berdel, W. R. E. Bausert, U. Fink, J. Rastetter and P. G. Munder. Anticancer Res., 1, 345 (1981).
4. D. J. Hanahan, P. G. Munder, K. Satouchi, L. Mcmanus and R. N. Pinckard, Biochem. Biophys. Res. Commun., 99, 183 (1981).
5. H. A. Neumann, D. B. J. Herrmann and D. Boerner, J. Natl. Cancer Inst., 78, 1087 (1987).
6. P. Hilgard, J. Stekar, R. Voegeli, J. Engel, W. Schumacher, H. Eibl, C. Unger and M. R. Berger, Eur. J. Cancer Clin. Oncol., 24, 1457 (1988).
7. K. Ukawa, E. Imamiya, H. Yamamoto, K. Mizuno, A. Tasaka, Z. Terashita, T. Okutani, H. Nomura, T. Kasukabe, M. Hozumi, I. Kudo and K. Inoue, Chem. Pharm. Bull., 37, 1249 (1989).
8. F. Paltauf, “Ether Lipids, Biochemical and Biomedical Aspects,” ed. by H. K. Mangold and F. Paltauf, Academic Press, N. Y., 1983, p. 213.
9. H. Eibl and C. Ungel, “Mammakarzinome Phospholipide als Antitumormittel, Ein Neues Konzept,” ed. by G. A. Nagel, Springer-Verlag Berlin, Heidelberg, FRG, 1986. pp. 124—132.
10. E. A. M. Fleer, C. Unger, D. J. Kim and H. Eibl, Lipids, 22, 856 (1987).
11. L. Purdom, E. J. Ambrose and G. A. Klein, Nature (London), 181, 1586 (1958).
12. T. S. Tenforde, P. O. Adesida, L. S. Kell and P. W. Todd, Eur. J. Cancer Clin. Oncol., 19, 277 (1983).
13. I. Kudo, S. Nojima, H. W. Chang, R. Yanoshita, H. Hayashi, E. Kondo, H. Nomura and K. Inoue, Lipids, 22, 862 (1987).
14. Y. Honma, T. Kasukabe, M. Hozumi, S. Tsushima and H. Nomura, Cancer Res., 41, 3211 (1981).
15. Y. Honma, T. Kasukabe, J. Okabe-kado, M. Hozumi, S. Tsushima and H. Nomura, Cancer Chemother. Pharmacol., 11, 73 (1983).
16. Y. Honma, T. Kasukabe, J. Okabe-kado, M. Hozumi, S. Tsushima and H. Nomura, Cancer Chemother. Pharmacol., 11, 77 (1983).
17. S. Tsushima, Y. Yoshioka, S. Tanida, H. Nomura, S. Nojima and M. Hozumi, Chem. Pharm, Bull., 32. 2700 (1984).
18. S. Tsushima, Y. Yoshioka, S. Tanida, H. Nomura, S. Nojima and M. Hozumi, Chem. Pharm. Bull., 30, 3260 (1982).
19. E. V. Dehmlow, Anew.Chem., 89, 521 (1977).
20. N. Takaishi, K. Urata and Y. Inamoto, Japan. Patent Unexamined Publication 56–063974 (1981) [Chem. Abstr., 95, 187047 (1981).
21. W. E. Berdel, U. Fink, B. Egger, A. Reichert, P. G. Munder and J. Rastetter, J. Natl. Cancer Inst., 66, 813 (1981).
22. T. Mosmann, J. Immunol. Methods, 65, 55 (1983).
23. H. Nomura, K. Ukawa, M. Hozumi, E. Kondo, I. Kudo and K. Inoue, Abstracts of Papers, 3rd Intern. Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids, Tokyo, May 1989, L. 50; b) I. Kudo and K. Inoue, private communication.
24. M. Hozumi, “Advances in Cancer Research, “Vol. 38, ed. by G. Klein and S. Weinhouse, Academic Press, New York, 1983, pp. 121—169; M. Hozumi, “CRC Critical Reviews in Oncology/Hematology,” Vol. 3, CRC Press, Boca Raton, 1985, pp. 235-237.
25. Y. Honma, T. Kasukabe, M. Hozumi, H. Akimoto and H. Nomura, Abstracts of Papers, 3rd Intern. Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids, Tokyo, May 1989, L. 52.
26. K. Sasajima, M. Miyashita, T. Shirota, E. Uchida, M. Onda and C. C. Harris, J. Cellular Biochemistry, Suppl. 13B D326, 1989, 55; K. Sasajima, M. Miyashita, T. Shirota, M. Onda, and H. Nomura, Abstracts of Papers, The 9th Sapporo Cancer Seminar, Sapporo, July 1989, p. 75.